标题
Trends in kinase drug discovery: targets, indications and inhibitor design
作者
关键词
-
出版物
NATURE REVIEWS DRUG DISCOVERY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-08-05
DOI
10.1038/s41573-021-00252-y
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases
- (2021) Zhouling Xie et al. JOURNAL OF MEDICINAL CHEMISTRY
- Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update
- (2021) Robert Roskoski PHARMACOLOGICAL RESEARCH
- DNA Repair Pathways in Cancer Therapy and Resistance
- (2021) Lan-ya Li et al. Frontiers in Pharmacology
- Hi-JAK-ing the ubiquitin system: The design and physicochemical optimisation of JAK PROTACs
- (2020) Rishi R. Shah et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
- (2020) George M. Burslem et al. CELL
- Selective inhibitors for JNK signalling: a potential targeted therapy in cancer
- (2020) Qinghua Wu et al. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
- Tumour-agnostic therapies
- (2020) Ann-Marie Looney et al. NATURE REVIEWS DRUG DISCOVERY
- Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
- (2020) Todd M. Bauer et al. Targeted Oncology
- Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
- (2020) Elias Jabbour et al. AMERICAN JOURNAL OF HEMATOLOGY
- Quantifying Target Occupancy of Small Molecules Within Living Cells
- (2020) M.B. Robers et al. Annual Review of Biochemistry
- Design and synthesis of selective degraders of EGFRL858R/T790M mutant
- (2020) Xin Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- An updated patent review of p38 MAP kinase inhibitors (2014-2019)
- (2020) Vanessa Haller et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme
- (2020) William J Sandborn et al. Journal of Crohns & Colitis
- Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase
- (2020) Volker K. Schulze et al. JOURNAL OF MEDICINAL CHEMISTRY
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Lorecivivint, a Novel Intra‐articular CLK/DYRK1A Inhibitor and Wnt Pathway Modulator for Treatment of Knee Osteoarthritis: A Phase 2 Randomized Trial
- (2020) Yusuf Yazici et al. Arthritis & Rheumatology
- Research Progress of Small Molecule VEGFR/c-Met Inhibitors as Anticancer Agents (2016–Present)
- (2020) Qian Zhang et al. MOLECULES
- The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K
- (2020) Mikołaj Słabicki et al. NATURE
- Functional characterization of a PROTAC directed against BRAF mutant V600E
- (2020) Ganna Posternak et al. Nature Chemical Biology
- Recent advances in Bcr‐Abl tyrosine kinase inhibitors for overriding T315I mutation
- (2020) Juan Liu et al. Chemical Biology & Drug Design
- First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo
- (2020) Mingming Wei et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase
- (2020) Bikash Adhikari et al. Nature Chemical Biology
- Kinase inhibition in autoimmunity and inflammation
- (2020) Ali A. Zarrin et al. NATURE REVIEWS DRUG DISCOVERY
- KLIFS: an overhaul after the first 5 years of supporting kinase research
- (2020) Georgi K Kanev et al. NUCLEIC ACIDS RESEARCH
- Functions of p38 MAP Kinases in the Central Nervous System
- (2020) Prita R. Asih et al. Frontiers in Molecular Neuroscience
- Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development
- (2020) Katherine A. Donovan et al. CELL
- Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2
- (2020) Chunjian Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Selectively Targeting Tropomyosin Receptor Kinase A (TRKA) via PROTACs
- (2020) Weiguo Xiang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Open Targets Platform: supporting systematic drug–target identification and prioritisation
- (2020) David Ochoa et al. NUCLEIC ACIDS RESEARCH
- Molecular mechanisms and pathobiology of oncogenic fusion transcripts in epithelial tumors
- (2019) Musaffe Tuna et al. Oncotarget
- PROTAC-Mediated Degradation of Bruton’s Tyrosine Kinase Is Inhibited by Covalent Binding
- (2019) Christopher P. Tinworth et al. ACS Chemical Biology
- Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models
- (2019) Philipp Haselmayer et al. JOURNAL OF IMMUNOLOGY
- Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
- (2019) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting RIPK1 for the treatment of human diseases
- (2019) Alexei Degterev et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis
- (2019) Kang-kang Chen et al. Frontiers in Oncology
- Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment
- (2019) V. Deshmukh et al. OSTEOARTHRITIS AND CARTILAGE
- Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
- (2019) Chune Yu et al. Frontiers in Immunology
- Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
- (2019) Alessandro Leonetti et al. BRITISH JOURNAL OF CANCER
- Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
- (2019) Kata P. Szilveszter et al. Frontiers in Immunology
- Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019)
- (2019) Concepción Sánchez-Martínez et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases
- (2019) Petra Hillmann et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors
- (2019) Harald Engelhardt et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Landscape of Atypical and Eukaryotic Protein Kinases
- (2019) Georgi K. Kanev et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Recent Progress in Rare Oncogenic Drivers and Targeted Therapy For Non-Small Cell Lung Cancer
- (2019) Yijia Guo et al. OncoTargets and Therapy
- Design, Synthesis, and Evaluation of Highly Potent FAK-Targeting PROTACs
- (2019) Hongying Gao et al. ACS Medicinal Chemistry Letters
- Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
- (2019) Timothy P. Hughes et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Cysteinome of Protein Kinases as a Target in Drug Development
- (2018) Apirat Chaikuad et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer
- (2018) C Ricordel et al. ANNALS OF ONCOLOGY
- Targeting Fyn Kinase in Alzheimer’s Disease
- (2018) Haakon B. Nygaard BIOLOGICAL PSYCHIATRY
- Netarsudil Ophthalmic Solution 0.02%: First Global Approval
- (2018) Sheridan M. Hoy DRUGS
- Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)
- (2018) Chengwei Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors
- (2018) Sharan K. Bagal et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361)
- (2018) Michael P. Smolinski et al. JOURNAL OF MEDICINAL CHEMISTRY
- Role and targeting of anaplastic lymphoma kinase in cancer
- (2018) Carminia Maria Della Corte et al. Molecular Cancer
- Unexplored therapeutic opportunities in the human genome
- (2018) Tudor I. Oprea et al. NATURE REVIEWS DRUG DISCOVERY
- Impact of a five-dimensional framework on R&D productivity at AstraZeneca
- (2018) Paul Morgan et al. NATURE REVIEWS DRUG DISCOVERY
- Kinase inhibitors: the road ahead
- (2018) Fleur M. Ferguson et al. NATURE REVIEWS DRUG DISCOVERY
- FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers HarboringBRAF V600EMutations
- (2018) Lauretta Odogwu et al. ONCOLOGIST
- A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee
- (2018) V. Deshmukh et al. OSTEOARTHRITIS AND CARTILAGE
- Targeting the intracellular signaling “STOP” and “GO” pathways for the treatment of alcohol use disorders
- (2018) Dorit Ron et al. PSYCHOPHARMACOLOGY
- Chemoproteomics and Chemical Probes for Target Discovery
- (2018) Gerard Drewes et al. TRENDS IN BIOTECHNOLOGY
- Orphan Drugs and Their Impact on Pharmaceutical Development
- (2018) Misty M. Attwood et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- A comprehensive review of protein kinase inhibitors for cancer therapy
- (2018) Radhamani Kannaiyan et al. Expert Review of Anticancer Therapy
- Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1
- (2018) Joseph Schoepfer et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeted therapy in patients with PIK3CA-related overgrowth syndrome
- (2018) Quitterie Venot et al. NATURE
- SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate
- (2018) Mary E. Matyskiela et al. Nature Chemical Biology
- Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
- (2018) Kim Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis
- (2018) Yvette L. Kasamon et al. ONCOLOGIST
- 422PFirst-in-human study of the monopolar spindle 1 (Mps1) kinase inhibitor BAY 1161909 in combination with paclitaxel in subjects with advanced malignancies
- (2018) P Lorusso et al. ANNALS OF ONCOLOGY
- Binding Kinetics Survey of the Drugged Kinome
- (2018) Victoria Georgi et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017
- (2017) Selma Ugurel et al. EUROPEAN JOURNAL OF CANCER
- The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review)
- (2017) Fatima Ardito et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1
- (2017) Andrew P. Crew et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases
- (2017) Philip A. Harris et al. JOURNAL OF MEDICINAL CHEMISTRY
- The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
- (2017) Andrew A. Wylie et al. NATURE
- A water-mediated allosteric network governs activation of Aurora kinase A
- (2017) Soreen Cyphers et al. Nature Chemical Biology
- Trends in GPCR drug discovery: new agents, targets and indications
- (2017) Alexander S. Hauser et al. NATURE REVIEWS DRUG DISCOVERY
- The kinase TPL2 activates ERK and p38 signaling to promote neutrophilic inflammation
- (2017) Kate Senger et al. Science Signaling
- Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex
- (2017) Jon S. Zawistowski et al. Cancer Discovery
- The kinase TPL2 activates ERK and p38 signaling to promote neutrophilic inflammation
- (2017) Kate Senger et al. Science Signaling
- Targeting the ATR-CHK1 Axis in Cancer Therapy
- (2017) Stuart Rundle et al. Cancers
- Bivalent Inhibitors of c-Src Tyrosine Kinase That Bind a Regulatory Domain
- (2016) Taylor K. Johnson et al. BIOCONJUGATE CHEMISTRY
- Small-molecule kinase inhibitors: an analysis of FDA-approved drugs
- (2016) Peng Wu et al. DRUG DISCOVERY TODAY
- DNA-Encoded Library Screening Identifies Benzo[b][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase Inhibitors
- (2016) Philip A. Harris et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation
- (2016) I. C. Waizenegger et al. MOLECULAR CANCER THERAPEUTICS
- Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase
- (2016) Georg Petzold et al. NATURE
- Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
- (2016) Yong Jia et al. NATURE
- Induced protein degradation: an emerging drug discovery paradigm
- (2016) Ashton C. Lai et al. NATURE REVIEWS DRUG DISCOVERY
- Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes
- (2016) Robert Roskoski PHARMACOLOGICAL RESEARCH
- VEGF-A/VEGFR2 signaling network in endothelial cells relevant to angiogenesis
- (2016) Chandran S. Abhinand et al. Journal of Cell Communication and Signaling
- Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis
- (2015) Feng-Che Kuan et al. BRITISH JOURNAL OF CANCER
- Ten things you should know about protein kinases: IUPHAR Review 14
- (2015) Doriano Fabbro et al. BRITISH JOURNAL OF PHARMACOLOGY
- Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma
- (2015) Q. Yang et al. CLINICAL CANCER RESEARCH
- Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration
- (2015) João P. L. Daher et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Neuroinflammation in Alzheimer's disease
- (2015) Michael T Heneka et al. LANCET NEUROLOGY
- Prolonged and tunable residence time using reversible covalent kinase inhibitors
- (2015) J Michael Bradshaw et al. Nature Chemical Biology
- The ins and outs of selective kinase inhibitor development
- (2015) Susanne Müller et al. Nature Chemical Biology
- The history and future of targeting cyclin-dependent kinases in cancer therapy
- (2015) Uzma Asghar et al. NATURE REVIEWS DRUG DISCOVERY
- KLIFS: a structural kinase-ligand interaction database
- (2015) Albert J. Kooistra et al. NUCLEIC ACIDS RESEARCH
- A historical overview of protein kinases and their targeted small molecule inhibitors
- (2015) Robert Roskoski PHARMACOLOGICAL RESEARCH
- PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations
- (2015) Helen Y. Zou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- FDA-approved small-molecule kinase inhibitors
- (2015) Peng Wu et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor
- (2015) Alexei S. Karpov et al. ACS Medicinal Chemistry Letters
- Aurora Kinase Inhibitors: Current Status and Outlook
- (2015) Vassilios Bavetsias et al. Frontiers in Oncology
- Recent Progress in the Design, Study, and Development of c-Jun N-Terminal Kinase Inhibitors as Anticancer Agents
- (2014) Abdellah Messoussi et al. CHEMISTRY & BIOLOGY
- Bivalent inhibitors of protein kinases
- (2014) Carrie M. Gower et al. CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Nintedanib: First Global Approval
- (2014) Paul L. McCormack DRUGS
- Regulation of Experimental Autoimmune Encephalomyelitis by TPL-2 Kinase
- (2014) S. Sriskantharajah et al. JOURNAL OF IMMUNOLOGY
- Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
- (2014) Ted W. Johnson et al. JOURNAL OF MEDICINAL CHEMISTRY
- Clinical development success rates for investigational drugs
- (2014) Michael Hay et al. NATURE BIOTECHNOLOGY
- A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics
- (2014) Apirat Chaikuad et al. Nature Chemical Biology
- FDA Approval Summary: Crizotinib for the Treatment of Metastatic Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements
- (2014) D. Kazandjian et al. ONCOLOGIST
- A Comparison of Protein Kinases Inhibitor Screening Methods Using Both Enzymatic Activity and Binding Affinity Determination
- (2014) Amalie Frederikke Rudolf et al. PLoS One
- A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1
- (2014) T. Justin Rettenmaier et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Advances in kinase targeting: current clinical use and clinical trials
- (2014) Mathias Rask-Andersen et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- The landscape of kinase fusions in cancer
- (2014) Nicolas Stransky et al. Nature Communications
- The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication
- (2013) Mathias Rask-Andersen et al. Annual Review of Pharmacology and Toxicology
- Structure-based discovery of cellular-active allosteric inhibitors of FAK
- (2013) Naoki Tomita et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Selective Bisubstrate Inhibitors with Sub-nanomolar Affinity for Protein Kinase Pim-1
- (2013) Ramesh Ekambaram et al. ChemMedChem
- Afatinib: First Global Approval
- (2013) Rosselle T. Dungo et al. DRUGS
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
- (2013) J. Kronke et al. SCIENCE
- Deciphering the Structural Basis of Eukaryotic Protein Kinase Regulation
- (2013) Hiruy S. Meharena et al. PLOS BIOLOGY
- The MPS1 Family of Protein Kinases
- (2012) Xuedong Liu et al. Annual Review of Biochemistry
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of 7-Methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a Potent and Selective First-in-Class Inhibitor of Protein Kinase R (PKR)-like Endoplasmic Reticulum Kinase (PERK)
- (2012) Jeffrey M. Axten et al. JOURNAL OF MEDICINAL CHEMISTRY
- Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles
- (2012) Iana M Serafimova et al. Nature Chemical Biology
- Application of MM-GB/SA and WaterMap to SRC Kinase Inhibitor Potency Prediction
- (2012) Anna Kohlmann et al. ACS Medicinal Chemistry Letters
- Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
- (2011) C. A. Dinarello BLOOD
- Pharmacophore Design of p38α MAP Kinase Inhibitors with Either 2,4,5-Trisubstituted or 1,2,4,5-Tetrasubstituted Imidazole Scaffold
- (2011) T. Scior et al. CURRENT MEDICINAL CHEMISTRY
- Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival
- (2011) Paul Morgan et al. DRUG DISCOVERY TODAY
- Understanding the Impact of the P-loop Conformation on Kinase Selectivity
- (2011) Cristiano R. W. Guimarães et al. Journal of Chemical Information and Modeling
- Trends in the exploitation of novel drug targets
- (2011) Mathias Rask-Andersen et al. NATURE REVIEWS DRUG DISCOVERY
- The Discovery of VX-745: A Novel and Selective p38α Kinase Inhibitor
- (2011) John P. Duffy et al. ACS Medicinal Chemistry Letters
- Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site
- (2010) Doriano Fabbro et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Regulation and function of TPL-2, an IκB kinase-regulated MAP kinase kinase kinase
- (2010) Thorsten Gantke et al. CELL RESEARCH
- Structural Determinants of PERK Inhibitor Potency and Selectivity
- (2010) Hong Wang et al. Chemical Biology & Drug Design
- Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs
- (2010) J A DiMasi et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases
- (2010) Kurt J Cox et al. Future Medicinal Chemistry
- Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant
- (2010) Wei-Sheng Huang et al. JOURNAL OF MEDICINAL CHEMISTRY
- MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
- (2010) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors
- (2010) Jianming Zhang et al. NATURE
- The (un)targeted cancer kinome
- (2010) Oleg Fedorov et al. Nature Chemical Biology
- Post-translational modifications in signal integration
- (2010) Yonathan Lissanu Deribe et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Why do Kinase Inhibitors Cause Cardiotoxicity and What can be Done About It?
- (2010) Hui Cheng et al. PROGRESS IN CARDIOVASCULAR DISEASES
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- Allosteric IGF-1R Inhibitors
- (2010) Timo Heinrich et al. ACS Medicinal Chemistry Letters
- "Go upstream, young man": lessons learned from the p38 saga
- (2009) D Hammaker et al. ANNALS OF THE RHEUMATIC DISEASES
- Extended kinase profile and properties of the protein kinase inhibitor nilotinib
- (2009) Paul W. Manley et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Interview with Jürg Zimmermann, Global Head of Oncology & Exploratory Chemistry at Novartis
- (2009) Jürg Zimmermann Future Medicinal Chemistry
- Through the “Gatekeeper Door”: Exploiting the Active Kinase Conformation
- (2009) Fabio Zuccotto et al. JOURNAL OF MEDICINAL CHEMISTRY
- SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo
- (2009) S. G. Buchanan et al. MOLECULAR CANCER THERAPEUTICS
- Kinase mutations in human disease: interpreting genotype–phenotype relationships
- (2009) Piya Lahiry et al. NATURE REVIEWS GENETICS
- Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
- (2009) A F Gazdar ONCOGENE
- Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib
- (2008) Oliver Hantschel et al. LEUKEMIA & LYMPHOMA
- A quantitative analysis of kinase inhibitor selectivity
- (2008) Mazen W Karaman et al. NATURE BIOTECHNOLOGY
- Do molecularly targeted agents in oncology have reduced attrition rates?
- (2008) Ian Walker et al. NATURE REVIEWS DRUG DISCOVERY
- A helix scaffold for the assembly of active protein kinases
- (2008) A. P. Kornev et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now